Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $170.77, for a total value of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at approximately $91,221,235.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Illumina, Inc. (ILMN) traded down 1.10% during mid-day trading on Thursday, reaching $171.97. The company had a trading volume of 653,969 shares. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48. The firm has a 50 day moving average of $175.68 and a 200-day moving average of $170.24. The stock has a market capitalization of $25.11 billion, a P/E ratio of 34.80 and a beta of 0.84.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. The company had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. Illumina’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.71 earnings per share. Analysts forecast that Illumina, Inc. will post $3.63 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/20/insider-selling-illumina-inc-ilmn-director-sells-15000-shares-of-stock.html.

Institutional investors have recently made changes to their positions in the stock. Advocacy Wealth Management Services LLC acquired a new position in shares of Illumina during the first quarter valued at approximately $102,000. Gemmer Asset Management LLC increased its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Illumina during the first quarter valued at approximately $117,000. Patten Group Inc. increased its position in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. increased its position in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 93.73% of the company’s stock.

Several research analysts have weighed in on ILMN shares. Piper Jaffray Companies reissued an “overweight” rating and issued a $187.00 price objective (up previously from $170.00) on shares of Illumina in a research report on Friday, April 14th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective on the stock in a research report on Tuesday, April 4th. Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $188.84 price objective on the stock. in a research report on Monday, March 27th. Cantor Fitzgerald boosted their price objective on Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 26th. Finally, Leerink Swann reissued a “buy” rating on shares of Illumina in a research report on Wednesday, April 5th. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and a consensus target price of $166.54.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.